Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Johnson & Johnson

JNJ Pharmaceuticals Unknown Updated July 11, 2026
$256.93
52W $154.80 – $269.43
64/100
$623.71B
29.7
0.23
Price History (6M)
AI Committee Verdict
Buy
Conviction: Contested · 67% agreement · 6 analysts
-14.2%
100%
Executive Summary
6 analysts weighed in with 67% agreement on a bullish lean. Growth Analyst: Quarter-over-quarter growth rate is ACCELERATING, not just positive. Risk Analyst: Bollinger bandwidth of 19.7% signals elevated volatility. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
  • Positive MACD histogram signals bullish momentum.
  • Daily trend: uptrend.
  • Weekly trend: uptrend.
  • Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
Insufficient data for bear case.
AI Investment Committee
Committee Consensus As of July 11, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Contested
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst bullish
63 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 19.7% signals elevated volatility
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
55 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bullish
75 / 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Open Full Terminal →
Technical Analysis
RSI (14)
55.5
Neutral
MACD Histogram
0.900
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.69
Inside Bands
Price vs Moving Averages
EMA 9
$257.34 Below
EMA 21
$249.82 Above
EMA 50
$241.44 Above
EMA 200
$220.99 Above
Fundamental Analysis
Valuation
35
Growth
48
Profitability
100
Financial Health
57
Valuation
P/E Ratio 29.7×
P/B Ratio 6.13×
PEG Ratio
Dividend Yield 2.07%
52W High $269.43
52W Low $154.80
Quality & Growth
ROE 2626.0%
ROA 1070.0%
Gross Margin 6795.0%
Operating Margin 2588.0%
Revenue Growth YoY +787.0%
Debt / Equity 0.59
AI Fundamental Assessment
P/E ratio of 29.7 (moderate relative to a 15-40x range); Price-to-book of 6.1x; Revenue growth (YoY) of 7.9%; EPS growth (YoY) of -3.9%; Return on equity of 26.3%; Return on assets of 10.7%; Net margin of 21.8%; Gross margin of 68.0%; Current ratio of 1.03 (tight short-term liquidity); Debt-to-equity of 0.59; Most recent quarter beat estimates by 0.3%; EPS growth accelerating (-12.1% -> +9.8% QoQ); Analyst estimates falling over recent quarters
Key Risks
Risk data not available for JNJ.
Get the Full JNJ Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime